



Kidney Health Evaluation for Patients with Diabetes (KED)

For 2022, the Medical Attention for Nephropathy measure is a quality metric for several of our Medicare Advantage programs, including Amerigroup and Humana. However, in 2023, this measure will be transitioned to the Kidney Health Evaluation for Patients with Diabetes (KED) measure. The KED measure was implemented into our BCBS Commercial quality program as a reporting-only metric in 2021, but we anticipate it will likely become a performance metric in the upcoming years as well. Since the KED measure will require an annual eGFR in addition to an annual uACR, we will begin educating proactively to prepare for this transition.

Measure Compliance: Patients 18–85 years of age with diabetes (type 1 and type 2) need to have a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) **AND** a urine albumin-creatinine ratio (uACR), during the measurement year.

- Note: Patients should receive both tests during the measurement year, but these can be on the same or different dates of service.

Exclusions:

- Patients with ESRD.
- Patients receiving dialysis.
- Patients receiving palliative care or hospice services
- Patients 66 years of age or older with an applicable advanced illness and frailty code assessed in the measurement year
- Patients enrolled in an Institutional SNP
- Patients living in a long-term care facility